Article info

Download PDFPDF

Original research
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Authors

  1. Correspondence to Dr Victor H Engelhard; vhe{at}virginia.edu
View Full Text

Citation

Engelhard VH, Obeng RC, Cummings KL, et al
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Publication history

  • Accepted April 7, 2020
  • First published May 7, 2020.
Online issue publication 
May 07, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.